@article{85c027e1a667461f8f850ded5f57a3e4,
title = "Outcomes consequent to “early” COPD for interventional studies (I)",
author = "Rennard, {Stephen I.}",
note = "Funding Information: Conflict of interest: S.I. Rennard was an employee of AstraZeneca until 30 November, 2019 and holds shares in the company; and has received funding from the tobacco industry for studies relating to harm reduction and to the impact of tobacco smoke on stem cells; he also consulted with RJ Reynolds without personal fee on the topic of harm reduction; he received funding from RJ Reynolds to evaluate the effect of a harm reduction product in normal smokers (1996) and in subjects with chronic bronchitis (1999) and to assess the effect of smoking cessation on lower respiratory tract inflammation (2000); he participated in a Philip Morris multicentre study to assess biomarkers of smoke exposure (2002); he received funding for a clinical trial from the Institute for Science and Health (2005), which receives support from the tobacco industry, to evaluate biomarkers in exhaled breath associated with smoking cessation and reduction; this study was supplemented with funding from Lorillard and RJ Reynolds; he received a grant from the Philip Morris External Research Program (2005) to assess the impact of cigarette smoking on circulating stem cells in the mouse; he consulted with RJ Reynolds on the topic of harm reduction until 2007, but did not receive personal remuneration for this. There are no active tobacco-industry funded projects. All ties with tobacco industry companies and entities supported by tobacco companies were terminated in 2007.",
year = "2020",
month = mar,
day = "1",
doi = "10.1183/13993003.02380-2019",
language = "English (US)",
volume = "55",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",
}